Recent news on Torsemide

PRESZCATOR & HOUGHTON RULINGS  -  May 7, 2007
Harnesslink,On March 30, 2007, Preszcator had been issued a $1500 fine and a 60-day suspension after a positive test for the Class 3 drug Torsemide.

RULING ON ZHOK  -  Apr 25, 2007
Harnesslink,The appeal by trainer Randy Zhok of an Ontario Racing Commission ruling on a positive test for the Class 3 drug Torsemide has been denied.

RULING ON ZHOK  -  26 Apr 2007
Harnesslink,The appeal by trainer Randy Zhok of an Ontario Racing Commission ruling on a positive test for the Class 3 drug Torsemide has been denied.

ORC DIRECTIVE ON STAYS  -  Apr 17, 2007
Harnesslink,Furthermore, trainers Wayne Prezscator and Paul Walter have been issued stays by the ORC pending their appeal hearings for Class III positives (Torsemide).

Trainer used diuretic 'in good faith'  -  Feb 21, 2007
Canoe.ca,Wayne Preszcator of Exeter is one of 15 individuals whose horses tested positive recently for torsemide, a diuretic that can enhance performance.

WAYNE PRESZCATOR SPEAKS OUT  -  Feb 21, 2007
Harnesslink,Trainer Wayne Preszcator says he bought torsemide in good faith to alleviate a 'tie up' problem in his horse and didn't know it was a banned substance.

Racing to clean up image  -  Feb 20, 2007
SLAM! Sports,Last week the ORC announced it is investigating 20 positive tests for the diuretic torsemide. Considered a "Class 3" substance, guilty parties face a

Preszcator Speaks Out  -  Feb 21, 2007
Standardbred Canada,...shared with the London Free Press staff when asked about Simply Mavelous' positive test for torsemide, a diuretic that can enhance performance.

Banned drugs detected in recent tests  -  Feb 20, 2007
SLAM! Sports,Torsemide: The diuretic is a Class 3 drug and thus not subject to penalties as severe as the above pair. In humans, it is used to treat high blood pressure.

ORC REPORTS 20 POSITIVES  -  Feb 16, 2007
Harnesslink,The positive tests for the banned substance torsemide were reported during this period, and involved 15 individuals. Torsemide, a diuretic, is a Class III

Endo and Penwest Agree to Amend Opana(R) ER Contract  -  Jan 8, 2007
Drug Newswire (press release),...regulatory risks relating to drugs in development such as torsemide ER and nalbuphine ER, including the timing and outcome of regulatory action;

DGAP-News: Sanochemia Pharmazeutika AG boosts sales revenues and ...  -  Dec 5, 2006
Financial.de,The top-sellers continue to be synthesis products such as galantamine and torsemide. The R&D division reports its first substantial contribution to group

Penwest to Participate In Upcoming Conferences  -  Nov 28, 2006
Drug Newswire (press release),...regulatory risks relating to drugs in development such as, torsemide ER and nalbuphine ER, including the timing and outcome of regulatory action;

SANOCHEMIA: Patent Awarded for Torsemide Synthesis Products  Oct 31, 2006
Pharmazeutika AG announced on Tuesday the award of the Austrian patent (AT 500576) entitled “Method for the preparation of crystal forms of torsemide in a ... -ag-IP-news Agency, DGAP-News: Sanochemia Pharmazeutika AG: Patent awarded for ...  Oct 30, 2006
Exchange (ISIN AT0000776307), announces the award of the Austrian patent (AT 500576) entitled 'Method for the preparation of crystal forms of torsemide in a ... -Financial.de, Sanochemia Awarded Blood Pressure Drug Production Patent  Oct 31, 2006
...manufacturer Sanochemia Pharmazeutika AG (SAC.XE) Tuesday said it has been awarded an Austrian patent for its specialized production of torsemide, an active ... -Therapeutics Daily (subscription) (press release), Penwest Reports Third Quarter and Nine Month 2006 Financial ...  Oct 31, 2006
This increase was primarily due to increased spending on nalbuphine ER and torsemide ER, as well as the stock-based compensation charge noted above. ... -MSN Money Foro de Shell Security - Seguridad informática  Oct 26, 2006
...nodular patter toradol , which vaguely recapitulate normal B-cell lymphoid follicular torsemide structures, are generally less aggressive than lymphomas t ... -Shell Security, Penwest Named One of Connecticut's Fastest Growing Technology ...  Oct 13, 2006
...as Endo to, among other things, sell products for which Penwest receives royalties; regulatory risks relating to drugs in development such as, torsemide ER and ... -Yahoo! News (press release) Penwest Falls As Baird Starts Coverage  Sep 19, 2006
..."Opana ER may not be the only story over the next three to five years, as the more advanced products in the pipeline, Torsemide ER (for swelling) and ... -Houston Chronicle

Penwest to Present at 2006 UBS Global Life Sciences Conference  Sep 17, 2006
...as Endo to, among other things, sell products for which Penwest receives royalties; regulatory risks relating to drugs in development such as, torsemide ER and ... -Drug Newswire

DGAP-News: Sanochemia Pharmazeutika AG boosts sales revenues and ...  -  Dec 5, 2006
Financial.de,The top-sellers continue to be synthesis products such as galantamine and torsemide. The R&D division reports its first substantial contribution to group

Penwest to Participate In Upcoming Conferences  -  Nov 28, 2006
Drug Newswire (press release),...regulatory risks relating to drugs in development such as, torsemide ER and nalbuphine ER, including the timing and outcome of regulatory action;

Penwest to Initiate Dispute Resolution Procedures Under Agreement ...  Aug 16, 2006
...as Endo to, among other things, sell products for which Penwest receives royalties; regulatory risks relating to drugs in development such as, torsemide ER and ... -Yahoo! News

Penwest Reports Second Quarter and Six-Month 2006 Financial ...  Jul 26, 2006
...offset by decreased spending on PW2101, a project the Company determined it would discontinue in the second quarter of 2005, and on its torsemide ER product ... -MSN Money

Penwest Awaits FDA Decision  Jun 21, 2006
In addition to watching Endo’s rollout, we hope to see Penwest advance its pipeline programs for Nalbuphine ER, another product for pain, and Torsemide ER, a ... -Forbes

Penwest Announces That Endo Reports Receiving Final FDA Approval ...  Jun 23, 2006
...among other things, sell products for which the Company receives royalties; regulatory risks relating to drugs in development such as, torsemide ER, nalbuphine ... -Yahoo! News



Penwest Reports First Quarter 2006 Financial Results  Apr 27, 2006
...among other things, sell products for which the Company receives royalties; regulatory risks relating to drugs in development such as, torsemide ER, nalbuphine ... - MSN Money

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional